BioDelivery Sciences Announces Further Improved Insurance Coverage for BELBUCA®
09 juil. 2019 08h00 HE
|
BioDelivery Sciences International, Inc.
Regional Commercial Plans Improved Access for More Than 6 Million Lives During 2Q More Than 90% of Commercial Lives Now Have Access to BELBUCA in the U.S. RALEIGH, N.C., July 09, 2019 (GLOBE...
BioDelivery Sciences Expands Upon Report from Pain Management Task Force
24 juin 2019 08h00 HE
|
BioDelivery Sciences International, Inc.
Company’s Activities Support Buprenorphine Recommendations Including: Primary Use of Buprenorphine in Chronic Pain when Clinically IndicatedHaving Payers Provide Coverage and Reimbursement for...
BioDelivery Sciences Named to the Russell 3000® Index
20 juin 2019 08h00 HE
|
BioDelivery Sciences International, Inc.
RALEIGH, N.C., June 20, 2019 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI) is set to be added to the broad-market Russell 3000® Index as well as the Russell 2000® Index...
BioElectronics Announces Publication of Study Verifying the Effectiveness of Its ActiPatch Medical Device on Chronic Pain
03 juin 2019 09h31 HE
|
BioElectronics Corporation
FREDERICK, MD, June 03, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- BioElectronics Corporation (OTC PINK: BIEL) www.bielcorp.com, the maker of non-invasive electroceutical devices, is pleased to...
BioDelivery Sciences Announces Upcoming Investor Conference Presentations
29 mai 2019 16h10 HE
|
BioDelivery Sciences International, Inc.
RALEIGH, N.C., May 29, 2019 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI), a rapidly growing commercial-stage specialty pharmaceutical company dedicated to patients...
BioDelivery Sciences Strengthens Financial Position with Debt Refinancing
28 mai 2019 16h10 HE
|
BioDelivery Sciences International, Inc.
New Agreement is Cash Flow Accretive, Lowers Cost of Capital and Extends Debt Maturity Reduces Annual Interest Costs by Approximately $1.5 million Increases Flexibility to Continue Growth Trajectory...
BioDelivery Sciences Reports Strong First Quarter 2019 Results and Raises BELBUCA® Full-Year Expectations
06 mai 2019 16h05 HE
|
BioDelivery Sciences International, Inc.
BELBUCA® Net Sales Increased by 134% versus Prior Year to All-time High of $18.7 MillionSymproic® Acquisition and Commercial Integration Successfully CompletedCompany Raises Full-Year BELBUCA Net...
BioDelivery Sciences to Report First Quarter 2019 Financial Results
25 avr. 2019 16h30 HE
|
BioDelivery Sciences International, Inc.
RALEIGH, N.C., April 25, 2019 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI), a rapidly growing commercial stage specialty pharmaceutical company dedicated to patients...
BioDelivery Sciences International, Inc. Announces Proposed Underwritten Public Offering of Common Stock
10 avr. 2019 16h07 HE
|
BioDelivery Sciences International, Inc.
RALEIGH, N.C., April 10, 2019 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (Nasdaq: BDSI) (“BDSI” or the “Company”) today announced that it is commencing an underwritten public...
BioDelivery Sciences Acquires U.S. Commercial Rights to Symproic®
10 avr. 2019 16h06 HE
|
BioDelivery Sciences International, Inc.
Long-term revenue potential of over $75 million for NME with IP protection through 2031 Leverages existing commercial capabilities to provide a novel treatment option for OIC ...